Strong Buy
Average AnalystStrong Buy
Top AnalystBullish
Stock Target AdvisorHold
Average UserUSD 74.22
0.00 (0.00%)
USD 228.18B
3.61M
USD 87.38(+17.73%)
Based on the AstraZeneca PLC ADR stock forecast from 5 analysts, the average analyst target price for AstraZeneca PLC ADR is USD 87.38 over the next 12 months. AstraZeneca PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AstraZeneca PLC ADR is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, AstraZeneca PLC ADR’s stock price was USD 74.22. AstraZeneca PLC ADR’s stock price has changed by +0.87% over the past week, +8.83% over the past month and +15.73% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers median on a price to book value basis.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.